The data from TCGA showed that the expression of SLC7A11 was negatively correlated (p < 0.0001) with the expression of METTL3 in BC patients (Fig. 8G), suggesting an in vivo correlation of the METTL3/SLC7A11 axis with disease progression. This evidence concerns the gene METTL3 and breast cancer.